Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med's NDA for Surufatinib Accepted by China's NMPA for Review

publication date: Nov 14, 2019

Hutchison China MediTech (Chi-Med) said its NDA for surufatinib was accepted for review by China's NMPA as a treatment for advanced non-pancreatic neuroendocrine tumors. If approved, surufatinib would become Chi-Med's second commercialized drug, following fruquintinib one year ago. A novel oral kinase inhibitor, surufatinib works by promoting tumor angiogenesis and limiting immune evasion. In a Phase III trial, which was stopped early because surufatinib met its endpoints, surufatinib increased median progression free survival from 3.8 months in the placebo group to 9.2 months in the active cohort. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.